Safety findings aligned with prior batoclimab experience, with no emergent safety liabilities reported across the phase 3 ...

Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials signals ...

The DPP1 inhibitor did not beat placebo in this trial, leaving branded Bimzelx and Cosentyx, as well as Humira and its ...

Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. The British Big Pharma ...

Eli Lilly and Company announced Thursday morning that its GLP-1 drug tirzepatide cut the risk of heart failure by 38% in a Phase 3 trial. Tirzepatide – better known by its name brands Mounjaro for ...